Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CD24 and Mutant p53: Emerging Therapeutic Targets in Prostate Cancer Progression.

Anti-cancer agents in medicinal chemistry - 1 Jan 2026

Qinzhamusu Yin, Xintian Lan, Zhihao Gan, Tiezheng Han, Ming Zhu, Ruishi Xie, Yi Guo, Yong Wang

Abstract excerpt

INTRODUCTION: Prostate cancer is a leading cause of cancer-related mortality in men worldwide, and the treatment of metastatic castration-resistant prostate cancer (mCRPC) remains a major clinical challenge. CD24, a glycosylated cell surface protein, plays a critical role in tumor progression and immune evasion. This review focuses on the role of CD24 in prostate cancer pathogenesis, particularly its interaction...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to CD24 Antigen

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Disease Progression

Share to TP53 gene

Share to Mutation

Share to Prostatic Neoplasms

Share to Tumor Suppressor Protein p53

Source

Identifiers

PMID: 41503910
DOI: 10.2174/0118715206405420251117053720

Genes

CD24
TP53

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CD24 and Mutant p53: Emerging Therapeutic Targets in Prostate Cancer Progression.PMID 41503910Read ↗

Silencing of CD24 Enhances the PRIMA-1–Induced Restoration of Mutant p53 in Prostate Cancer CellsSemantic proximity Read ↗

Intracellular CD24 disrupts the ARF-NPM interaction and enables mutational and viral oncogene-mediated p53 inactivation.Semantic proximity Read ↗

A CD24‐p53 axis contributes to African American prostate cancer disparitiesSemantic proximity Read ↗

TP53 Deficiency in the Natural History of Prostate CancerSemantic proximity Read ↗

CD24 is a genetic modifier for risk and progression of prostate cancer.Semantic proximity Read ↗

Surprising magic of CD24 beyond cancerSemantic proximity Read ↗

Novel insights into the function of CD24 : A driving force in cancerSemantic proximity Read ↗

Nuclear CD24 Drives Tumor Growth and Is Predictive of Poor Patient PrognosisSemantic proximity Read ↗

Mutant Kras-induced upregulation of CD24 enhances prostate cancer stemness and bone metastasisSemantic proximity Read ↗

APOBEC3B-driven mutations negatively regulated by P53 promote tumor progression and immunosuppressive microenvironment in prostate cancer.Semantic proximity Read ↗

The Metastasis-Associated Gene <i>CD24</i> Is Regulated by Ral GTPase and Is a Mediator of Cell Proliferation and Survival in Human CancerSemantic proximity Read ↗

Activation of p53 and destabilization of androgen receptor by combinatorial inhibition of MDM2 and MDMX in prostate cancer cellsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.